Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma | Zendy

Daniel D. Von Hoff | Zendy; Patricia LoRusso | Zendy; Charles M. Rudin | Zendy; Josina C. Reddy | Zendy; Robert L. Yauch | Zendy; Raoul Tibes | Zendy; Glen J. Weiss | Zendy; Mitesh J. Borad | Zendy; Christine L. Hann | Zendy; Julie R. Brahmer | Zendy; Howard Mackey | Zendy; B. Lum | Zendy; Walter C. Darbonne | Zendy; James C. Marsters | Zendy; Frédéric J. de Sauvage | Zendy; Jennifer A. Low | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

Author(s) -

Daniel D. Von Hoff,

Patricia LoRusso,

Charles M. Rudin,

Josina C. Reddy,

Robert L. Yauch,

Raoul Tibes,

Glen J. Weiss,

Mitesh J. Borad,

Christine L. Hann,

Julie R. Brahmer,

Howard Mackey,

B. Lum,

Walter C. Darbonne,

James C. Marsters,

Frédéric J. de Sauvage,

Jennifer A. Low

Publication year - 2009

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0905360

Subject(s) - smoothened , patched , ptch1 , basal cell carcinoma , hedgehog signaling pathway , hedgehog , vismodegib , medicine , cancer research , basal (medicine) , gene , biology , genetics , basal cell , insulin

Mutations in hedgehog pathway genes, primarily genes encoding patched homologue 1 (PTCH1) and smoothened homologue (SMO), occur in basal-cell carcinoma. In a phase 1 clinical trial, we assessed the safety and pharmacokinetics of GDC-0449, a small-molecule inhibitor of SMO, and responses of metastatic or locally advanced basal-cell carcinoma to the drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research